ALNYLAM PHARDRNALNYLAM PHARDRNALNYLAM PHARDRN

ALNYLAM PHARDRN

No trades
See on Supercharts

Key stats

Market capitalization
‪96.16 B‬BRL
Dividend yield (indicated)
Price to earnings Ratio (TTM)
Basic EPS (TTM)
Net income
Revenue
Shares float
Beta (1Y)
0.19

About ALNYLAM PHARDRN

CEO
Yvonne L. Greenstreet
Headquarters
Cambridge
Founded
2002
ISIN
BRA1LNBDR003
FIGI
BBG00XV4BP79
Alnylam Pharmaceuticals, Inc. is a global commercial-stage biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. Its products include ONPATTRO, GIVLAARI, and OXLUMO. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. Schimmel, and Phillip A. Sharp on June 14, 2002 and is headquartered in Cambridge, MA.

See all ideas 

Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Curated watchlists where A1LN34 is featured.